Background:
Patients with type 2 diabetes mellitus (T2DM), heart failure (HF), and chronic kidney disease (CKD) remain at high risk for renal deterioration, glycaemic emergencies, and adverse cardiovascular outcomes despite contemporary therapy. Although sodium-glucose cotransporter-2 inhibitors (SGLT2i) improve car...
Emmanuel Adjei-Wiafe, G. Blankson, E. Ansah et al.· Circulation· 0 citations
Background Atrial fibrillation (AF) frequently coexists with Heart Failure with Preserved Ejection Fraction, particularly in patients with Type 2 Diabetes, due to shared cardiometabolic and inflammatory mechanisms. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated cardiovascular benefit in HFpEF, but...
I. Acheampong, G. Blankson, Dennis D. Kumi et al.· The Cardiology· 0 citations
BACKGROUND
Ninety percent of left atrial thrombi in nonvalvular atrial fibrillation arise in the left atrial appendage, which can be occluded percutaneously (left atrial appendage closure [LAAC]). Two 2026 trials (CHAMPION-AF and CLOSURE-AF) more than doubled the available randomized evidence comparing LAAC with oral a...
P. Pekyi-Boateng, A. Mahadevan, S. Frimpong et al.· Stroke· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.